Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04486833 · ClinicalTrials.gov registry record · Phase 1
Quaratusugene Ozeplasmid (Reqorsa) and Osimertinib in Patients With Advanced Lung Cancer Who Progressed on Osimertinib
A Phase 1 study of Carcinoma, Non-Small Cell Lung, sponsored by Genprex.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 158
- Enrollment target
- 10
- Study locations
NCT04486833 is a Phase 1 study of Carcinoma, Non-Small Cell Lung that is actively recruiting participants, run by Genprex. The registered enrollment target is 158 participants, below the 323-participant average among 130 other Carcinoma, Non-Small Cell Lung trials with a reported enrollment target (51% lower). The trial reports 10 study locations across 9 states.
The verdict
NCT04486833, a Phase 1 study of Carcinoma, Non-Small Cell Lung, is actively recruiting participants, sponsored by Genprex.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 158 participants
- Enrollment target
- 10
- Study locations
Study Summary
The purpose of this randomized study is to determine the safety and efficacy of quaratusugene ozeplasmid (Reqorsa) added to osimertinib in NSCLC patients with activating EGFR mutations who have progressed while on treatment with osimertinib. Quaratusugene ozeplasmid consists of non-viral lipid nanoparticles that encapsulate a DNA plasmid with the TUSC2 tumor suppressor gene and is the first systemic gene therapy for cancer. The study is comprised of a Phase 1 dose escalation portion and two Phase 2 portions evaluating safety and efficacy. Enrollment in the Phase 1 dose escalation portion is complete and the recommended Phase 2 dose (RP2D) was determined. Phase 2a has initiated and enrolled patients are treated with quaratusugene ozeplasmid at the RP2D in combination with osimertinib. In Phase 2b, patients will be randomized to receive either quaratusugene ozeplasmid plus osimertinib or platinum-based chemotherapy.
Conditions Studied
Interventions
- DRUG osimertinib
- BIOLOGICAL quaratusugene ozeplasmid
- DRUG Platinum-Based Chemotherapy
Study Locations (10)
Virginia
- Virginia Cancer Specialists - Fairfax
- Virginia Oncology Associates - Norfolk
California
- Valkyrie Clinical Trials - Los Angeles
Colorado
- Rocky Mountain Cancer Centers - Lone Tree
Illinois
- Carle Cancer Institute - Urbana
Kentucky
- Markey Cancer Center - Lexington
Maryland
- Maryland Oncology Hematology - Rockville
New Jersey
- The Valley Hospital - Luckow Pavilion - Paramus
Ohio
- Gabrail Cancer Center Research - Canton
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 158 participants |
| Start Date | 2021-09-03 |
| Est. Completion | 2029-03 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04486833
The ClinicalTrials.gov registry entry for NCT04486833 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 158 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 323-participant average among 130 other Carcinoma, Non-Small Cell Lung trials with a reported enrollment target (51% lower). The listed sponsor is Genprex, which has 4 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Carcinoma, Non-Small Cell Lung appearing as the primary indexed condition, and to 3 interventions - of which osimertinib is the first listed.
NCT04486833 reports 10 study locations spanning 9 distinct geographic areas - top geographies include Virginia, California, Colorado.
Frequently Asked Questions
What is clinical trial NCT04486833 about?
NCT04486833 is a clinical study titled "Quaratusugene Ozeplasmid (Reqorsa) and Osimertinib in Patients With Advanced Lung Cancer Who Progressed on Osimertinib". The purpose of this randomized study is to determine the safety and efficacy of quaratusugene ozeplasmid (Reqorsa) added to osimertinib in NSCLC patients with activating EGFR mutations who have progressed while on treatment with osimertinib. Quaratusugene ozeplasmid consists of non-viral lipid nanop...
What is the current status of trial NCT04486833?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 158 participants. The study started on 2021-09-03. Estimated completion is 2029-03.
What conditions does trial NCT04486833 study?
This clinical trial studies the following conditions: Carcinoma, Non-Small Cell Lung.
What interventions are being tested in trial NCT04486833?
The interventions under investigation include: osimertinib (DRUG), quaratusugene ozeplasmid (BIOLOGICAL), Platinum-Based Chemotherapy (DRUG).
Who is sponsoring clinical trial NCT04486833?
This trial is sponsored by Genprex, which has 4 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04486833 being conducted?
This trial has 10 study locations across California, Colorado, Illinois, Kentucky, Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Carcinoma, Non-Small Cell Lung
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Different Anticancer Agents in Advanced Cancers
RECRUITING · Phase 1
-
A Study of Sigvotatug Vedotin in Advanced Solid Tumors
RECRUITING · Phase 1
-
A Study of PF-08046054/SGN-PDL1V in Advanced Solid Tumors
RECRUITING · Phase 1
-
A Study to Learn About the Study Medicine PF-07934040 When Given Alone or With Other Anti-cancer Therapies in People With Advanced Solid Tumors That Have a Genetic Mutation.
RECRUITING · Phase 1
-
A Study of LY4175408 in Participants With Advanced Cancer
RECRUITING · Phase 1
-
A Study of Amivantamab and Olomorasib Combination Therapy in Participants With Metastatic Non-Small Cell Lung Cancer
RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.